Lori Abney
Nurse Practitioner · Campbellsburg, KYNPI 1053654509
Payments from drug & device makers
Across 281 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$792
- AbbVie$721
- Novo Nordisk$507
- Lilly USA, LLC$426
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$307
- GSK$277
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,721100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $792 |
| AbbVie | 55 | $721 |
| Novo Nordisk | 32 | $507 |
| Lilly USA, LLC | 26 | $426 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $307 |
| GSK | 15 | $277 |
| Boehringer Ingelheim | 16 | $259 |
| Amgen | 14 | $219 |
| Esperion Therapeutics, Inc. | 11 | $175 |
| Exact Sciences | 7 | $108 |
| Abbott | 6 | $98 |
| Axsome Therapeutics, Inc. | 5 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $91 |
| Bayer | 4 | $79 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $77 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $63 |
| Novartis | 4 | $56 |
| Pfizer | 3 | $54 |
| Kowa Pharmaceuticals America, Inc. | 3 | $45 |
| UCB, Inc. | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Merck | 2 | $29 |
| Dexcom, Inc. | 2 | $28 |
| Vertex | 1 | $23 |
| Tris Pharma Inc | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
| Astellas Pharma US Inc | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,732 in reported general payments places this provider in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 72 | $77,523 |
| TrulicityDulaglutide | 48 | $53,956 |
| MounjaroTirzepatide | 30 | $46,516 |
| JanuviaSitagliptin Phosphate | 26 | $42,358 |
| JardianceEmpagliflozin | 29 | $35,015 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $32,281 |
| FarxigaDapagliflozin Propanediol | 28 | $26,115 |
| OzempicSemaglutide | 18 | $24,862 |
| XareltoRivaroxaban | 27 | $24,353 |
| Memantine Hcl ErMemantine Hcl | 36 | $12,440 |
| Repatha SyringeEvolocumab | 17 | $11,494 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $10,723 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $6,932 |
| VascepaIcosapent Ethyl | 16 | $6,663 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $6,623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $426 | $100,47278 claims |
| PfizerEliquis, Paxlovid | $54 | $78,93683 claims |
| MerckJanuvia, Janumet Xr | $29 | $53,08137 claims |
| Boehringer IngelheimJardiance, Jentadueto | $259 | $41,14142 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $277 | $38,90453 claims |
| AstraZenecaFarxiga, Symbicort | $792 | $31,12650 claims |
| Novo NordiskOzempic | $507 | $24,86218 claims |
| Johnson & JohnsonXarelto | $20 | $24,35327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Campbellsburg
- Rachael BradfordLexington$447K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Courtney BowlingCampbellsville$47K
- Rebecca BraunerLouisville$40K
- Scott SeitzWinchester$34K
- Kristen KreinestEdgewood$34K
- Lillian ArgentEdgewood$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.